Impact of CYP2C19 genetic variation on the association between CYP2B6 genotype and plasma steady-state OH-BUP to bupropion ratio (study 1)
| B | β | 95% CI | P | |
|---|---|---|---|---|
| OH-BUP/BUP model without CYP2C19a | ||||
| CYP2B6 NM>IM>SM | −6.48 | −0.38 | −11.5 to -1.43 | 0.01* |
| OH-BUP/BUP model with CYP2C19b | ||||
| CYP2B6 NM>IM>SM | −6.88 | −0.40 | −12.3 to −1.51 | 0.01* |
| CYP2C19*2 | −2.13 | −0.09 | −9.78 to 5.51 | 0.58 |
| CYP2C19*17 | 2.50 | 0.11 | −4.64 to 9.64 | 0.48 |
| Likelihood Ratio χ2c | 1.44 | |||
| P | 0.49 | |||
IM, intermediate metabolizers; NM, normal metabolizers; SM, slow metabolizers (Zhu et al., 2012; Benowitz et al., 2013).
↵a The association between CYP2B6 genotype and plasma steady state OH-BUP/BUP ratio.
↵b The association between CYP2B6 genotype and plasma steady state OH-BUP/BUP ratio after controlling for CYP2C19 genotype.
↵c Comparing the likelihood of the model without CYP2C19 versus with CYP2C19, adjusting for CYP2C19 did not significantly alter the association between CYP2B6 and plasma steady state OH-BUP/BUP ratio.
↵* Indicates statistical significance.